Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants

被引:49
作者
Jeffrey, Gary P.
MacQuillan, Gerry
Chua, Fern
Galhenage, Sam
Bull, Judith
Young, Emma
Hulse, Gary
O'Neil, George
机构
[1] Sir Charles Gairdner Hosp, Dept Gastroenterol Hepatol, Perth, WA 6009, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
[3] Univ Western Australia, Sch Psychiat, Perth, WA 6009, Australia
[4] Univ Western Australia, AMPRF, Perth, WA 6009, Australia
关键词
METHADONE-MAINTENANCE; PLUS RIBAVIRIN; ALCOHOL-USE; INTERFERON; INFECTION; IMPACT; MANAGEMENT; ADHERENCE; MORPHINE; THERAPY;
D O I
10.1002/hep.21470
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The effectiveness of HCV antiviral therapy in patients who have undergone recent drug dependency treatment and continue to inject drugs sporadically is presently not clear. Patients attending a community-based drug rehabilitation and naltrexone implant clinic from October 2002 until March 2005 were screened for HCV infection and if positive offered further assessment and treatment with interferon and ribavirin therapy. The first 50 patients to commence HCV therapy and complete at least 6 months follow-up were prospectively studied. ETR response (HCV PCR negative) was 34/50 (68%) and SVR 6 months post-treatment was 31/50 (62%). Viral eradication was maintained in those 22 patients that have had 12 months or more post-treatment follow-up. Eleven (22%) patients stopped therapy early due to side effects or poor compliance. Only two patients with an ETR likely reinfected due to unsafe injection practices. One was re-treated and achieved an SVR. Of the patients achieving a 6-month SVR, 17 of 31 patients reported no further IDU and 13 of 31 patients occasional IDU during treatment and this was maintained after HCV treatment cessation. 46% of patients received antidepressant and/or antipsychotic medication during treatment. Conclusion: This study of HCV treatment in a community-based subcutaneous naltrexone implant clinic found antiviral therapy resulted in a 62% SVR. This result is comparable to that reported in hospital-based clinics in non-IDU patients. The side effect profile and compliance was also similar. HCV antiviral therapy should be offered to this large and currently under treated group.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 33 条
  • [1] Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study
    Anand, Bhupinder S.
    Currie, Sue
    Dieperink, Eric
    Bin, Edmund J.
    Shen, Hui
    Ho, Samuel B.
    Wright, Teresa
    [J]. GASTROENTEROLOGY, 2006, 130 (06) : 1607 - 1616
  • [2] Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy
    Asselah, T
    Vidaud, D
    Doloy, A
    Boyer, N
    Martinot, M
    Vidaud, M
    Valla, D
    Marcellin, P
    [J]. GUT, 2003, 52 (06) : 900 - 902
  • [3] Treatment of hepatitis C infection in injection drug users
    Backmund, M
    Meyer, K
    Von Zielonka, M
    Eichenlaub, D
    [J]. HEPATOLOGY, 2001, 34 (01) : 188 - 193
  • [4] Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C
    Buti, M
    San Miguel, R
    Brosa, M
    Cabasés, JM
    Medina, M
    Casado, MA
    Fosbrook, L
    Esteban, R
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (05) : 639 - 645
  • [5] METHADONE-MAINTENANCE AND THE LIKELIHOOD OF RISKY NEEDLE-SHARING
    CAPLEHORN, JRM
    ROSS, MW
    [J]. INTERNATIONAL JOURNAL OF THE ADDICTIONS, 1995, 30 (06): : 685 - 698
  • [6] The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C
    Chang, A
    Skole, K
    Gautam, M
    Schmutz, J
    Black, M
    Thomas, R
    Horwitz, B
    Friedenberg, FK
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (08) : 701 - 706
  • [7] Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up
    Dalgard, O
    Bjoro, K
    Hellum, K
    Myrvang, B
    Skaug, K
    Gutigard, B
    Bell, H
    [J]. EUROPEAN ADDICTION RESEARCH, 2002, 8 (01) : 45 - 49
  • [8] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
  • [9] GEBER WF, 1975, ARCH INT PHARMACOD T, V214, P322
  • [10] Screening for depressive symptoms among HCV-infected injection drug users: Examination of the utility of the CES-D and the beck depression inventory
    Golub, ET
    Latka, M
    Hagan, H
    Havens, JR
    Hudson, SM
    Kapadia, F
    Campbell, JV
    Garfein, RS
    Thomas, DL
    Strathdee, SA
    [J]. JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2004, 81 (02): : 278 - 290